SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.